PL 265

Drug Profile

PL 265

Alternative Names: PL-265

Latest Information Update: 29 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmaleads
  • Class Analgesics
  • Mechanism of Action Aminopeptidase inhibitors; Neprilysin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Neuropathic pain
  • Preclinical Cancer pain; Dry eyes; Ocular pain

Most Recent Events

  • 29 Jun 2017 Pharmaleads plans a phase I (multiple ascending dose) trial for Neuropathic pain in United Kingdom before 2018
  • 12 May 2017 PL 265 is available for licensing as of 12 May 2017. http://pharmalead.nl/
  • 12 May 2017 Preclinical pharmacodynamics data in Ocular pain and Dry-eye syndrome released by Pharmaleads
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top